Consensus EPS · Q2 2026
-$0.32
Consensus revenue · Q2 2026
$1.6M
Analysts
8
Expected report
Aug 5, 2026
What to watch
- Analyst ratings: Mixed
Analyst consensus
Based on estimates from 8 analysts.
| Metric | Low | Consensus | High |
|---|---|---|---|
| Revenue | $1.6M | $1.6M | $1.6M |
| EPS | -$0.35 | -$0.32 | -$0.30 |
| EBITDA | -$1.6M | -$1.6M | -$1.6M |
| EBIT | -$1.6M | -$1.6M | -$1.6M |
| Net income | -$51.4M | -$45.5M | -$42.6M |
- Revenue$1.6M
- EPS-$0.32
- EBITDA-$1.6M
- EBIT-$1.6M
- Net income-$45.5M
Estimate revisions
How analyst consensus estimates have changed over the past 90 days.
| Metric | Now | 30d ago | 60d ago | 90d ago | 30d Δ |
|---|---|---|---|---|---|
| Revenue | $1.6M | $1.6M | — | — | 0% |
| EPS | -$0.32 | -$0.32 | — | — | +2.0% |
Community vs analysts
See how the TickerLeague crowd's forecast stacks up against Wall Street.
Be the first to predict
No community consensus for Tango Therapeutics (TNGX) Q2 2026 yet. Make a prediction to start the crowd forecast.
Analyst price target
Based on price targets from 1 analyst.
- Low
- $24.00
- Consensus
- $46.80
- Median
- $43.00
- High
- $69.00
- Current
- $27.18
- Upside
- +72.2%
Upside calculated vs most recent trading price of $27.18.
Consensus across all covering analysts. See the ranking ›
Analyst ratings
Consensus: Buy — based on 13 analyst ratings.
24-month trend
Recent analyst actions
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 17, 2026 | Mizuho | maintain | Outperform | Outperform |
| Jun 29, 2026 | Canaccord Genuity | maintain | Buy | Buy |
| Jun 26, 2026 | Jefferies | upgrade | Hold | Buy |
| Jun 11, 2026 | Canaccord Genuity | maintain | Buy | Buy |
| Jun 9, 2026 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jun 9, 2026 | Canaccord Genuity | maintain | Buy | Buy |
| Jun 8, 2026 | Leerink Partners | maintain | Outperform | Outperform |
| May 15, 2026 | Piper Sandler | downgrade | Overweight | Neutral |
| May 15, 2026 | Mizuho | maintain | Outperform | Outperform |
| May 14, 2026 | Wedbush | maintain | Outperform | Outperform |
- Jul 17, 2026MizuhoOutperform
- Jun 29, 2026Canaccord GenuityBuy
- Jun 26, 2026JefferiesBuy
- Jun 11, 2026Canaccord GenuityBuy
- Jun 9, 2026HC Wainwright & Co.Buy
- Jun 9, 2026Canaccord GenuityBuy
- Jun 8, 2026Leerink PartnersOutperform
- May 15, 2026Piper SandlerNeutral
- May 15, 2026MizuhoOutperform
- May 14, 2026WedbushOutperform
Frequently asked questions
Tango Therapeutics (TNGX) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.